Abstract Extensive evidence has demonstrated that psychological stress has detrimental effects on psychological health, cognitive function, and ultimately well-being. While stressful events are a significant cause of psychopathology, most individuals exposed to adversity maintain normal psychological functioning. The mechanisms underlying such resilience are poorly understood, and there is an urgent need to identify and target these mechanisms to promote resilience under stressful events. Botanicals have been used throughout history to treat various medical conditions; however, the development of botanical compounds into potential preventative and therapeutic agents in studies promoting brain health is hindered by the fact that most orally consumed botanicals are extensively metabolized during absorption and/or by postabsorptive xenobiotic metabolism. Therefore, the primary objective of this review article is to provide recommendations for developing natural compounds as novel therapeutic strategies to promote resilience in susceptible subjects. The development of botanical polyphenols to ultimately attenuate mood disorders and cognitive impairment will rely on understanding (1) the absorption and bioavailability of botanical polyphenols with emphasis on flavan-3-ols, (2) the characterization of tissue-specific accumulation of biologically available polyphenols and their mechanisms of action in the brain, and eventually (3) the characterization of biologically available polyphenol metabolites in mechanisms associated with the promotion of resilience against mood disorders and cognitive impairment in response to stress. We also summarize exciting new lines of investigation about the role of botanicals such as polyphenols in the promotion of cognitive and psychological resilience. This information will provide a strategical framework for the future development of botanicals as therapeutic agents to promote resilience, ultimately preventing and/or therapeutically treating cognitive impairment and psychological dysfunction.
Introduction
Over the past decade, there has been increasing attention paid to the phenomenon of resilience: the ability to maintain normal psychological and physical functioning and avoid serious mental illness when exposed to stress and trauma, even at extraordinary levels (Aburn et al. 2016; Kimhi 2016) . Although resilience has been identified across the spectrum of psychiatric disorders, we focus here on resilience as it relates to stress-induced depression and sleep deprivation (SD)-induced cognitive impairment. In this context, resilience refers to the capacity of an individual to cope with negative psychological and biological consequences of extreme stress that would otherwise compromise their psychological or physical well-being (Kimhi 2016; Kreutzer et al. 2016; Russo et al. 2012) . Recent reports indicate that resilience in humans is an active, adaptive process and not simply the absence of pathological responses that occur in more susceptible individuals (Russo et al. 2012 ). Anxiety and stress-related disorders are widespread psychological conditions with broad health implications, including negative impacts on cardiovascular and metabolic functions, as well as on mental health, leading to depression and memory dysfunction (Farzaei et al. 2016) . The concept of human resilience is difficult to operationalize as it encapsulates many divergent behavioral phenotypes (Russo et al. 2012) . Indeed, the study of human resilience is still a mostly phenomenological assessment of biological factors in resilient individuals that are associated with more successful coping responses (Kimhi 2016; Russo et al. 2012) . While stressful events are a significant cause of psychopathology, most individuals exposed to adversity maintain normal psychological functioning. The mechanisms underlying such resilience are poorly understood, and there is an urgent need to identify and target these mechanisms to promote resilience under stressful events. Certain botanicals, used throughout history to treat various medical conditions, provide a unique opportunity to target these mechanisms and ultimately promote neuroresilience in response to stress. The development of botanical polyphenols to ultimately attenuate mood disorders and cognitive impairment will rely on understanding (1) the absorption and bioavailability of botanical polyphenols with emphasis on flavan-3-ols, (2) the characterization of tissue-specific accumulation of biologically available polyphenols and their mechanisms of action in the brain, and eventually (3) the characterization of biologically available polyphenol metabolites in mechanisms associated with the promotion of resilience against mood disorders and cognitive impairment in response to stress. We also summarize exciting new lines of investigation about the role of botanicals such as polyphenols in the promotion of cognitive and psychological resilience. This information will provide a strategical framework for the future development of botanicals as therapeutic agents to promote resilience, ultimately preventing and/or therapeutically treating cognitive impairment and psychological dysfunction.
A Historical Perspective of Botanical Drug Discovery in Medicine
Throughout history, the development of drug blockbusters by the pharmaceutical industry has capitalized on the mechanistic investigation of natural compounds followed by subsequent clinical, pharmacological, and chemical studies. Since the 1940s, 131 (74.8 %) out of 175 small molecule anticancer drugs developed have been natural product-based/inspired, with 85 (48.6 %) being either natural products or derived from natural products (Newman and Cragg 2012) . Among the 20 approved small molecule new chemical entities in 2010, half of them are natural products (Newman and Cragg 2012) . The history of natural product discovery is full of remarkable stories of how the discovery of a natural product profoundly impacted advances in biology and therapy. An archetypical example is the discovery of the anti-inflammatory agent, acetylsalicylic acid, commonly known as aspirin, derived from the natural product Filipendula ulmaria (Schmidt et al. 2008) . Similarly, the discovery of the natural product Papaver somniferum (opium poppy) resulted in the isolation of several alkaloids including morphine (Schmidt et al. 2008) . Another typical example is Digitalis (foxglove), an herbaceous genus, which in the last three centuries was shown to produce a bioactive metabolite digitoxin, currently used to treat congestive heart failure (Schmidt et al. 2008) . Most recently, the Chinese traditional medicine artemisinin, isolated from the plant sweet wormwood, is now part of standard anti-malarial regimens; this discovery supported a Nobel Prize in Physiology or Medicine in 2015 (Kiani et al. 2016) . Undoubtedly, the discovery of new natural products promises significant advances in many fields of medicine, especially neurology and psychiatry. Unfortunately, the much needed research ranging from rigorous bioavailability studies to characterization of the bioactive metabolites to pharmacokinetic and pharmacodynamic studies is still for the most part unmet in the field of brain research. Remarkable progress has been made in the last few years in relation to the characterization of certain bioavailable bioactive polyphenolic metabolites that are capable of accumulating in the brain, which promises a great deal of opportunities for future development in the promotion of healthy cognitive function (Chen et al. 2015; Ferruzzi et al. 2009; Gasperotti et al. 2015; Ho et al. 2013; Margalef et al. 2016; Wang et al. 2015; Wang et al. 2012b) . Thanks to the support of federal funding, in particular from the National Center for Complementary and Integrative Health (NCCIH), the characterization of bioavailable bioactive polyphenolic metabolites will undoubtedly allow unparalleled new breakthroughs in the field of brain health rivaling the impact of acetylsalicylic acid (aspirin) on anti-inflammatory research.
Dietary Polyphenols in the Promotion of Cognitive and Psychological Resilience
Polyphenols are a class of phenolic compounds characterized by two or more benzene rings that each has at least one hydroxyl group (OH) attached and are found abundantly in fruits, such as berries and grapes, vegetables, tea, and other plant sources. Polyphenols have been found to possess a variety of health benefits, including cancer prevention , heart disease risk reduction (Jiang et al. 2010) , and protection against neurodegenerative disorders (Pasinetti 2012) . In preclinical studies, we found certain bioavailable, bioactive, and brain-penetrating polyphenols, particularly those among the flavonoid subclass found in commercially available Concord grape juice (CGJ) and grape seed polyphenol extract (GSPE), effectively promote neuronal plasticity mechanisms that play a major role in learning and memory functions (Ho et al. 2013; Wang et al. 2012b) . Consistent with these observations, Krikorian et al. 2010 demonstrated that 16 weeks of dietary supplementation with CGJ (15-21 oz. per day) significantly improved cognitive function of older adult subjects with mild cognitive impairment. Increasing evidence indicates that dietary polyphenols may help promote cognitive and/or psychological resilience. Primary polyphenolic constituents include flavonoids, which can further be subdivided into flavonols and flavanols, phenolic acids, and stilbenes. Previous bio-guided fractionation and bioavailability studies from our research group revealed that GSPE is rich in bioavailable flavanols (flavan-3-ols), including anthocyanidins such as catechin and epicatechin, and microbiome-derived phenolic acids; we also found that CGJ is rich in bioavailable flavonols, such as quercetin ( Fig. 1 ; Ferruzzi et al. 2009; Ho et al. 2013; Wang et al. 2015) . Studies from our laboratory and others also suggest that flavanol metabolites may benefit cognition, in part, by improving synaptic plasticity. Our observations provide the impetus to further develop select brain-bioavailable, bioactive catechin, epicatechin, and other brain-targeted proanthocyanidin metabolites to promote cognitive function (Kimhi 2016; Wang et al. 2008; Wang et al. 2012b ).
Implications of Bioavailability in the Characterization of Bioactive Polyphenol Metabolites
In order to develop polyphenols for the promotion of cognitive and psychological resilience, it is essential to explore the pharmacokinetics of specific polyphenolic preparations and the mechanistic basis of their bioactivities in the brain. Since orally consumed polyphenols almost exclusively accumulate in the brain in metabolite form, these studies are extremely important for the development of novel therapeutic drugs to deliver specific brain-available, bioactive polyphenol metabolites to recapitulate the biological activities of the original botanical polyphenolic compounds. Previous studies from us and others were designed to identify specific metabolites that may benefit brain function, such as synaptic plasticity. We previously demonstrated that oral administration of GSPE from the monomeric form of proanthocyanidins is able to improve cognitive function, and only metabolites derived from a monomeric form of GSPE were able to selectively reach and accumulate in the brain at a concentration of *400 nM (Wang et al. 2012b ). For example, we reported that a biosynthetic epicatechin metabolite, 3
, one of the proanthocyanidin metabolites identified in the brain following oral GSPE treatment, promotes basal synaptic transmission and long-term potentiation at physiologically relevant concentrations in hippocampal slices through mechanisms associated with cAMP response elementbinding protein (CREB) signaling (Fig. 2, adapted from  (Spencer 2009)) . These studies suggest that certain forms of proanthocyanidin metabolites may target the brain and benefit cognitive function through modulation of synaptic plasticity. These studies provide the impetus to develop the polyphenol, 3
0 -O-Me-EC-Gluc metabolite, among others, for further studies of learning and memory function (Wang et al. 2012b) , and demonstrate the importance of exploring the pharmacokinetics of specific polyphenolic preparations. Our studies have also demonstrated the essential approach of identifying select polyphenol-derived metabolites for targeting specific brain functions, which is consistent with previous evidence that catechin and epicatechin glucuronide metabolites may reach the brain and exert bioactivity (Abd El Mohsen et al. 2002; Abd El-Mohsen et al. 2006; Milbury and Kalt 2010) . Collectively, these studies strongly support the concept that characterization of select metabolites is a fundamental part of investigating dietary botanicals through bioavailability studies which can be eventually developed to selectively target specific brain functions.
Microbiome-Associated Metabolism of Polyphenols into Phenolic Metabolites
Development of polyphenols for brain health is complicated by the fact that most orally consumed polyphenols are extensively metabolized by gastrointestinal (GI) (Spencer 2009) epithelial cells during absorption and/or by post-absorptive xenobiotic metabolism. The majority of dietary polyphenols consumed are not absorbed by the upper intestinal track and are further broken down by the gut microbiota in the colon into low molecular weight phenolic compounds, such as phenolic acids, that can be more efficiently absorbed by GI epithelial cells ( Fig. 3 ; Calani et al. 2012; Monagas et al. 2010; Ozdal et al. 2016) . In vitro studies have demonstrated that isolated human fecal microbiota are capable of metabolizing polyphenol components from botanical supplements into smaller phenolic metabolites, particularly phenolic acids, including 3-hydroxyphenolic acetic acid, 3,4-dihydroxyphenylacetic acid, 3-(3 0 -hydroxyphenyl)propionic acid (3-HPP), and 3-(3 0 ,4 0 -dihydroxyphenyl)propionic acid (Aura et al. 2008 ). The formation of phenolic compounds from GSPE was anticipated based on previous observations from in vitro colonic microflora metabolism of flavonoids, including proanthocyanidins, and urinary output of phenolic acid following oral administration of flavonoids (Aura et al. 2002; Prasain et al. 2009; Rechner et al. 2004; Ward et al. 2004) .
Published evidence has also demonstrated that the gut microbial community (i.e., gut microbiota) plays a critical role in modulating bioconversion and bioavailability of bioactive phenolic metabolites, particularly phenolic acids, from orally consumed polyphenol-rich botanical supplements (Bolca et al. 2013; Chen et al. 2012; Selma et al. 2009; Wang et al. 2012a ). For example, evidence from our group revealed oral administration of certain botanical supplements leads to accumulation of multiple phenolic acids, such as 3,4-dihydroxyhydrocinnamic acid, 3-(3 0 -hydroxyphenyl) propionic acid, and homovanillic acid in circulating blood (Wang et al. 2015) . We observed an approximately tenfold reduction in the content of 3,4-dihydroxyhydrocinnamic acid and approximately 50 % reduction in content of 3-(3 0 -hydroxyphenyl) propionic acid and homovanillic acid in the plasma of germ-free gnotobiotic mice compared to conventionalized gnotobiotic mice (with normal microbiota harvested from wildtype mice) following oral administration of the botanical polyphenols (Pasinetti, unpublished observation) . These studies from our group and others strongly support the pivotal contribution of the GI microbiota in modulating bioconversion and bioavailability of bioactive phenolic acids from the botanical polyphenols that are relevant to health benefits, including the preservation of cognitive and psychological resilience (Bolca et al. 2013; Chen et al. 2012; Selma et al. 2009; Wang et al. 2012a) .
Based on these key issues in the characterization of bioactive polyphenol metabolites, we have been conducting studies on the role of polyphenols in the promotion of cognitive and psychological resilience; next we summarize exciting new lines of investigation that were made possible through the consideration of these factors.
Toward the Promotion of Resilience Against Stress-Induced Depression
An exciting line of investigation using bioactive bioavailable polyphenolic metabolites is the promotion of resilience against stress-induced depression and anxiety. Depression and anxiety are estimated to affect more than 50 million people in the USA alone. There is no effective strategy of prevention, and it is estimated that currently available antidepressants produce remission in less than 50 % of patients (Rush et al. 2009 ), which highlights the need for new, more selective therapeutics targeting underlying disease mechanisms. A number of recent human studies indicate that psychosocial stressors increase peripheral cytokine production and may be an important factor in the development of depression and anxiety (Dowlati et al. 2010; Maes et al. 1992 Maes et al. , 1997 Maes et al. , 2011 . Subsets of patients with major depressive disorder (MDD) have Fig. 3 Interpersonal differences in gut microbiota composition affect health benefits of polyphenol-rich botanicals. After oral consumption, monomeric (and to a lesser extent, dimeric) polyphenols are absorbed by the small intestine with or without enterocyte modification by phase II metabolism (e.g., glucuronidation). Most dietary polyphenols, particularly multimeric ones, are not absorbed by the small intestine and are passed to the colon where microbial metabolism converts them into simple phenols, such as phenolic acids. Some of these phenolic acids are absorbed, with or without colonocyte modification by phase II metabolism. Absorbed polyphenol metabolites and phenolic acids may undergo additional phase II metabolism, primarily by the liver, before they are delivered to target tissues, such as blood cells and the brain. The schematic depicts interpersonal microbiota diversity with ''red'' bacterial strains representing those required to generate select bioactive phenolic acids capable of modulating the cellular/molecular mechanisms underlying psychological and/or cognitive resilience (Color figure online) higher levels of multiple inflammatory markers, including the cytokine interleukin 6 (IL-6), the most consistently looked for cytokine (Maes et al. 1992 (Maes et al. , 1997 Miller et al. 2009 ). Although biological criteria are not used to diagnose depression, it is noteworthy that the newest diagnostic criteria for this disorder identify inflammation as a possible cause (Association 2013) . Moreover, a recent meta-analysis indicates that IL-6 is the most consistently elevated proinflammatory cytokine in the blood of patients with MDD (Dowlati et al. 2010) , and levels correlate with symptom severity in patients that do not respond to antidepressant treatment (Lanquillon et al. 2000) . It is estimated that approximately 30-60 % of patients with depression do not respond to approved antidepressant treatments (Krishnan and Nestler 2008) , which may reflect a heterogeneity in the mechanisms of depression that cannot be ubiquitously treated with standard antidepressants, including mechanisms such as systemic inflammation.
Thus, a promising approach to psychiatric drug development centers on screening compounds that promote resilience through anti-inflammatory properties. We have found that certain grape-derived polyphenol-rich botanicals have strong anti-inflammatory properties and can therefore promote psychological resilience and brain health through mediating IL-6 (Pasinetti, in preparation) . In addition, we have strong evidence that by reducing peripheral inflammation, such as IL-6 release from leukocytes, we can promote psychological resilience and brain health (Pasinetti, in preparation) . Thus, it is very likely that select bioavailable and bioactive phenolic metabolites reduce peripheral inflammation within leukocytes to reduce IL-6 production. In addition to reducing leukocyte-derived IL-6, select phenolic metabolites may also help promote psychological resilience by modulating expression of synaptic genes and, therefore, promote brain health and prevent maladaptive synaptic plasticity induced by environmental stressors, such as repeated social defeat stress (RSDS).
Toward the Promotion of Resilience Against Sleep Deprivation-Induced Cognitive Impairment
Another exciting line of investigation using bioactive bioavailable polyphenolic metabolites is the promotion of resilience against SD-induced cognitive impairment. Chronic sleep loss is a common problem in our society. An estimated 50-70 million US adults have sleep or wakefulness disorder (Colten et al. 2006) . Insufficient sleep is comorbid with chronic problems such as heart disease, kidney disease, high blood pressure, diabetes, obesity, and mental illness (Ford and Kamerow 1989; Gillin 1998; Hirotsu et al. 2010; Knutson and Van 2008; Najafian et al. 2013; Palagini et al. 2013; Vijayan 2012) . Sleep loss can also contribute to irritability, aggression, inattentiveness, and diminished psychomotor vigilance (Kamphuis et al. 2012; Rajaratnam 2001; Van Dongen et al. 2003) . The negative impact of sleep loss on physical and mental health places a strain on our healthcare system (Kapur et al. 2002) and a large financial burden on our economy (Goel et al. 2009 ). Unfortunately, many people are unable to obtain sufficient sleep on a daily basis. Therefore, it is important to explore the molecular and cellular impacts of sleep loss in an effort to identify novel therapeutic approaches to counteract these effects.
Natural dietary supplements have been used to treat stress and insomnia since Hippocrates and often have only mild side effects that are easily managed (Kinrys et al. 2009; Wollen 2010) . Select bioactive bioavailable polyphenolic metabolites derived from flavan-3-ols have extensive pharmacological action, including a pivotal role in mechanisms related to learning and memory consolidation. We recently demonstrated that oral administration with the botanical supplement mixture of GSPE, CGJ, and RSV attenuates SD-mediated memory impairments assessed by a contextual fear conditioning assay, and the improvement of memory consolidation processes coincided with the induction of the CREB transcription factor activity and induced the expression of immediate early genes (IEGs) in primary cortico-hippocampal neurons. This evidence was exciting especially in view of the fact that these changes were associated with an increased expression of proteins involved in the consolidation of short-into longterm memory in the brain. Thus, this evidence demonstrates that certain dietary polyphenols may beneficially promote resilience toward the preservation of cognitive function in models of SD and supports the better characterization and development of bioavailable bioactive polyphenolic metabolites from complex botanicals for clinical applications.
Conclusion
While there has been significant effort within the pharmaceutical and medical industries to develop treatments for mood disorders, such as anxiety and depression, and SDinduced cognitive dysfunction, currently available treatments often have extreme side effects and adverse drug reactions, as well as inconvenient drug-drug and fooddrug interactions. It is therefore necessary to challenge the prevailing and failing approach of the pharmaceutical industry by demonstrating the safe and efficacious role of novel botanical supplements (Qureshi and Al-Bedah 2013) . Moreover, characterizing GI microbial strains critical for the generation of specific bioactive phenolic metabolites that contribute to cognitive wellness and psychological resilience is highly innovative and will provide insight into broader issues related to the eventual goal of translation.
As schematized in Fig. 4 , successful translational studies of polyphenols will require coordinated research efforts bridging together innovative technologies with studies (1) identifying botanical preparations effective in modulating specific conditions and/or phenotypes, (2) characterizing dose-response tolerability and safety of specific bioactive botanical preparations in preclinical models, (3) characterizing metabolism and bioavailability of polyphenols leading to the detection and structural identification of polyphenol metabolites accumulated in target tissue(s), (4) investigating in vitro and in vivo the identified bioavailable forms for bioactivity relevant to specific health benefits under investigation and dissecting their mechanisms of action, (5) exploring the efficacy of the bioactive polyphenol metabolites to influence the desired phenotype in vivo in animal model systems, and finally (6) further investigating the role of the GI microbiome in the generation of select biologically available phenolic forms from orally consumed botanicals to promote therapeutic efficacy of the bioactive botanical preparation, which will eventually lead to better understanding the role of novel probiotics involved in phenolic acid generation. These considerations are critical for the development of botanical polyphenols into ''natural drugs'' for the promotion of resilience against stress-induced depression and cognitive impairment, among other conditions.
